SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas leaked and subsequently disclosed Phase 3 melanoma-vaccine results drove a sharp selloff: although the vaccine-plus-Keytruda combination reduced recurrence or death risk versus Keytruda alone, traders said the benefit fell short of expectations built into the stocks run-up. The community is split between calling it a sell-the-news reaction and viewing the data as a meaningful advance, while bears question the valuation and commercial prospects.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

A sharp selloff in WULF and other AI/data-center infrastructure stocks is fueling debate over sector weakness, financing needs, debt and dilution. Bulls view the decline as an oversold pullback, citing WULFs power and HPC hosting strategy and AI demand, while bears question execution and whether upcoming results will support the growth case.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energys strong Q3 results and raised full-year outlook were met with a sharp selloff, as traders focused on negative cash flow and elevated spending to expand capacity. Bulls view the drop as an overreaction and point to growth in data-center power demand, while skeptics question the valuation and cash generation.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

A sharp selloff in silver has driven attention to SLV, with traders reacting to persistent losses and questioning why the metal is falling despite its perceived safe-haven and inflation-hedge role. Some attribute the decline to a stronger dollar and rising yields, while others allege manipulation or see a buying opportunity; bearish traders warn the drop may continue.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. It operates through the Hard Disk Drives (HDD) segment. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digitals strong quarterly results and upbeat guidance are drawing attention, but shares sold off despite the report. Traders are debating whether the decline reflects broader weakness in AI and storage stocks and fears of a cyclical earnings peak, while bulls point to persistent AI-driven storage demand and continued pricing strength.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIAs decline is drawing attention amid a broader tech and semiconductor selloff, as traders debate whether AI infrastructure spending can be financed and sustained after Jensen Huangs comments about scarce capital. Bulls argue demand for AI compute remains strong and view the drop as a buying opportunity, while bears worry about debt, circular financing and a possible slowdown in AI spending.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor selloff, sparked by concerns about supply-chain constraints and compounded by broader doubts about AI spending and returns, has driven heavy attention to SOXL; its daily leveraged structure magnifies the sectors moves. Traders are split between calling the plunge an oversold buying opportunity and warning that the AI trade may face further declines.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as escalating Iran- and Houthi-related risks to Middle East oil infrastructure and shipping fuel concerns about supply disruption, lifting crude prices. Traders are divided between bulls focused on geopolitical risk and tighter supply, and bears who see the rally as headline-driven or vulnerable if shipping flows normalize and diplomacy advances.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is in focus after detailed Phase 3 results for its Keytruda combination with Modernas personalized melanoma vaccine showed reduced recurrence risk versus Keytruda alone. Traders are split between viewing the data as a meaningful oncology advance and seeing a sell-the-news reaction, with some questioning whether the results met elevated expectations or establish broader commercial potential.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

European regulators upheld their negative opinion on YARTEMLEA, renewing concerns about Omeros prospects in Europe and prompting debate over whether the selloff is an overreaction. Bulls point to U.S. launch momentum and upcoming sales results as the main counterweight, while skeptics say the company must prove demand can keep growing.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BMY Reports Mixed Phase III Trial Results, Stock Down

Bristol Myers Squibb reports mixed Phase III results for admilparant in IPF, while RYZ101 delivers a significant win in advanced GEP-NETs.

All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to Buy

Contineum Therapeutics, Inc. (CTNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Johnson & Johnson Partner Contineum Slides as Depression Drug Fails

Contineum Therapeutics shares fall as Phase 2 MOONLIGHT-1 depression trial fails primary endpoint. Partner J&J reviews additional trial data.read more...

CTNM Stock Slumps 10% After-Hours — What’s The JNJ Connection?

Equity

Contineum said that Johnson & Johnson’s (JNJ) mid-stage trial of JNJ-5120, also known as PIPE-307, failed to meet its main goal in major depressive disorder. 


Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that the MOONLIGHT-1 trial did not achieve its...

Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that management is scheduled to present at the...

Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its second-quarter 2026 financial results and...

Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice

Does Contineum Therapeutics, Inc. (CTNM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the publication of a manuscript describing the...

Are Medical Stocks Lagging  Adagene (ADAG) This Year?

Here is how Adagene Inc. Sponsored ADR (ADAG) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.

Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S. Lorrain on May 9, 2017 and is headquartered in San Diego, CA.

Contineum Therapeutics Inc. - Ordinary Shares - Class A

Bearish Sentiment

<ul class="summary-bullets"><li>The miss is the second mid-stage setback for the same molecule in less than a year.</li><li>J&amp;J licensed PIPE-307 worldwide in 2023 in a deal that included $50 million upfront, a $25 million equity stake, more than $1 billion in potential milestones, and royalties.</li><li>J&amp;J is still reviewing exploratory measures and has not said whether it will continue development.</li></ul><p><br>Shares of Contineum Therapeutics (CTNM) fell about 10% in after-hours trading on Monday after the firm said that Johnson &amp; Johnson’s (JNJ) mid-stage trial of JNJ-5120, also known as PIPE-307 and licensed from Contineum, failed to meet its main goal in major depressive disorder.</p><p>The miss is the second mid-stage setback for the same molecule in less than a year and shifts more of Contineum’s story onto its unpartnered lung-disease program. JNJ stock traded flat after-hours at the time of writing.</p><h2 class="st-heading-2">What The Trial Tested And Missed</h2><p>MOONLIGHT-1 was a randomized, placebo-controlled proof-of-concept study of JNJ-5120/PIPE-307 as a stand-alone treatment in adults with major depression. The primary measure was change from baseline on the Montgomery-Åsberg Depression Rating Scale, a standard depression score, at Day 5 versus placebo. That bar was not met. The drug was well tolerated, with no new safety issues, Contineum said. J&amp;J is still reviewing exploratory measures and has not said whether it will continue development.</p><p>J&amp;J licensed PIPE-307 worldwide in 2023 in a deal that included $50 million upfront, a $25 million equity stake, more than $1 billion in potential milestones, and royalties.</p><h2 class="st-heading-2">A Second Miss For The Same Asset</h2><p>In November 2025, Contineum’s own mid-stage VISTA trial of PIPE-307 in relapsing-remitting multiple sclerosis also missed its primary and secondary goals. Shares sold off after that readout, and analysts already treated the depression study as high-risk. Two efficacy misses leave the program’s future in J&amp;J’s hands.</p><p>Investors now focus on PIPE-791, a drug Contineum is developing itself for idiopathic pulmonary fibrosis and chronic pain. PROPEL-IPF, a global mid-stage trial of about 324 patients, began dosing in the first quarter of 2026. It measures change in lung function over 26 weeks, has more than 55 sites in eight countries, and is not expected to finish until mid-2028. Contineum has deferred a progressive-MS effort for PIPE-791 and paused another early program, CTX-343.</p><p>Contineum’s cash was $236.6 million as of June 30, which the company says funds operations through mid-2029 — past the planned IPF readout.</p><h2 class="st-heading-2">How Did CTNM, JNJ Retail Traders React?</h2><p>On Stocktwits, retail sentiment around CTNM stock went from ‘neutral’ to ‘bullish’ over the past 24 hours while message volume improved from ‘low’ to ‘normal’ levels.</p><p>Meanwhile, sentiment around JNJ stayed 'bearish.'</p><p>While <a href="https://stocktwits.com/symbol/CTNM">CTNM stock</a> has gained 30% year-to-date, <a href="https://stocktwits.com/symbol/JNJ">JNJ</a> gained 29%.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/srrk-shares-pull-back-after-fda-approval-for-genetic-disease-drug-but-wall-street-hikes-price-targets/cZtmh4bRBT3">SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Contineum Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Contineum said that Johnson & Johnson’s (JNJ) mid-stage trial of JNJ-5120, also known as PIPE-307, failed to meet its main goal in major depressive disorder. 

Johnson & Johnson

Very bullish

Cautiously bullish

Cautiously bearish

Very bearish

Stocktwits sentiment on $SPY just hit its lowest level of the year. How are you feeling about the market right now?

Stocktwits

 just hit its lowest level of the year. How are you feeling about the market right now?

Feed

News

Sentiment

Earnings

Fundamentals

Info

CTNM News